Literature DB >> 170385

Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.

G Subramanian, J G McAfee, R J Blair, F A Kallfelz, F D Thomas.   

Abstract

Methylene diphosphonate (MDP) was formulated as a complex of 99mTc for skeletal imaging. This agent was compared with three other bone-seeking technetium agents: ethane-1-hydroxy-1, 1-diphosphonate (EHDP), pyrophosphate, and polyphosphate. In tissue radioassay experiments in rodents, the technetium complexes of MDP and EHDP were similar, but skeletal concentration with both of these agents was higher than that with pyrophosphate or polyphosphate. The total-body retention of MDP and EHDP complexed with 95mTc was studied in beagle dogs for 35 days by excretion measurements and total-body counting and compared with polyphosphate and pertechnetate. The long-term retention was greater for MDP. The 5-day cumulative fecal excretion of 95mTc was low when administered as EHDP or polyphosphate complexes and negligible when administered as MDP complex. In six human volunteers the blood clearance of 99mTc-mdp was similar to that of 18F and significantly faster than that of 99mTc-EHDP. Pyrophosphate cleared from the blood much faster than polyphosphate but slower than the diphosphonates. The urinary excretion of the MDP complex was greater than for EHDP within the first 2-3 hr after injection. The 24-hr urinary excretion of pyrophosphate and polyphosphate complexes was not as complete as for the diphosphonates. All four 99mTc complexes proved satisfactory for clinical imaging studies. The MDP complex produced images of superior quality as early as 2 hr after administration, attributable to its more rapid clearance from the blood and soft tissues. On the contrary, a longer interval of 3-4 hr after injection was usually needed for 99mTc-EHDP; pyrophosphate and polyphosphate complexes regularly required a waiting period of 4 hr. Comparitive radiation dose estimates were made based on the available biologic distribution data for these 99mTc skeletal-localizing agents.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 170385

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  65 in total

1.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

2.  Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion--a refined index of bone metabolism.

Authors:  L Hyldstrup; P McNair; P Ring; O Henriksen
Journal:  Eur J Nucl Med       Date:  1987

3.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

4.  Finding sensitive parameters in internal dose calculations for radiopharmaceuticals commonly used in clinical nuclear medicine.

Authors:  Vladimir Spielmann; Wei Bo Li; Maria Zankl
Journal:  Radiat Environ Biophys       Date:  2018-06-29       Impact factor: 1.925

Review 5.  Role of radionuclide studies in paediatric orthopaedic practice: a review.

Authors:  H Carty; R Owen
Journal:  J R Soc Med       Date:  1985-06       Impact factor: 5.344

6.  Differences in biodistribution in rats injected with 99mTc-MDP preparations with different stabilizing agents.

Authors:  D E Heggli; P Franco; E Nørbygaard
Journal:  Eur J Nucl Med       Date:  1988

7.  Quantitative assessment of 99mTc-MDP scans in investigation of diffuse alterations in bone.

Authors:  J P Pfeifer; U Büll; H Pfeifer
Journal:  Eur J Nucl Med       Date:  1979-12

8.  Experimental examinations on the suitability of organoaminomethane-bis-phosphonic acids for bone-scintigraphy by means of Tc-99m in animals.

Authors:  S Unterspann
Journal:  Eur J Nucl Med       Date:  1976-08-12

9.  Technetium-1,2-dihydroxy-1,2-bis(dihydroxyphosphinyl)ethane (99mTc-DHPE). A promising new skeletal imaging agent.

Authors:  S C Archimandritis; A K Tsolis
Journal:  Eur J Nucl Med       Date:  1987

Review 10.  Strategies for the targeted delivery of therapeutics for osteosarcoma.

Authors:  Dennis P M Hughes
Journal:  Expert Opin Drug Deliv       Date:  2009-12       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.